136 related articles for article (PubMed ID: 37747442)
1. A meta-analysis of the efficacy and safety of first-line chemotherapeutic agents for osteosarcoma.
Li Z; Ma X; Wang Z; Dong S; Wang B
Adv Clin Exp Med; 2024 May; 33(5):445-454. PubMed ID: 37747442
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
Zhang B; Zhang Y; Li R; Li J; Lu X; Zhang Y
J Orthop Surg Res; 2020 Feb; 15(1):51. PubMed ID: 32054494
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis.
Ismail MD; Wiratnaya IGE; Raditya RH
Asian Pac J Cancer Prev; 2024 May; 25(5):1497-1505. PubMed ID: 38809621
[TBL] [Abstract][Full Text] [Related]
4. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation.
Yu D; Zhang S; Feng A; Xu D; Zhu Q; Mao Y; Zhao Y; Lv Y; Han C; Liu R; Tian Y
Medicine (Baltimore); 2019 May; 98(19):e15582. PubMed ID: 31083238
[TBL] [Abstract][Full Text] [Related]
6. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
7. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
10. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
Ferrari S; Mercuri M; Picci P; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Longhi A; Rimondini S; Donati D; Manfrini M; Ruggieri P; Biagini R; Bacci G
Tumori; 1999; 85(6):458-64. PubMed ID: 10774566
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
13. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
14. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
[TBL] [Abstract][Full Text] [Related]
15. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
[TBL] [Abstract][Full Text] [Related]
16. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
17. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
19. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
Ferrari S; Bielack SS; Smeland S; Longhi A; Egerer G; Sundby Hall K; Donati D; Kevric M; Brosjö O; Comandone A; Werner M; Monge O; Palmerini E; Berdel WE; Bjerkehagen B; Paioli A; Lorenzen S; Eriksson M; Gambarotti M; Tunn PU; Jebsen NL; Cesari M; von Kalle T; Ferraresi V; Schwarz R; Bertulli R; Kasparek AK; Grignani G; Krasniqi F; Sorg B; Hecker-Nolting S; Picci P; Reichardt P
Tumori; 2018; 104(1):30-36. PubMed ID: 29218692
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
Navid F; Santana VM; Neel M; McCarville MB; Shulkin BL; Wu J; Billups CA; Mao S; Daryani VM; Stewart CF; Kunkel M; Smith W; Ward D; Pappo AS; Bahrami A; Loeb DM; Reikes Willert J; Rao BN; Daw NC
Int J Cancer; 2017 Oct; 141(7):1469-1477. PubMed ID: 28631382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
